Genelux Co. (NASDAQ:GNLX – Get Rating) dropped 3.8% during mid-day trading on Thursday . The stock traded as low as $27.24 and last traded at $28.50. Approximately 36,234 shares traded hands during trading, a decline of 76% from the average daily volume of 151,273 shares. The stock had previously closed at $29.63.
Analysts Set New Price Targets
Separately, Benchmark initiated coverage on Genelux in a report on Wednesday, February 15th. They set a "speculative buy" rating and a $10.00 target price for the company.
Genelux Stock Down 5.5 %
Genelux Company Profile
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Articles
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.